243 | REAL‐WORLD OUTCOMES OF CD20xCD3 BISPECIFIC ANTIBODY THERAPY IN ADULT PATIENTS WITH RELAPSED/REFRACTORY TRANSFORMED INDOLENT LYMPHOMAP. Stéphan, Alexey V. Danilov, Karan Chohan et al.|Hematological Oncology|2025Cited by 1
161 | OUTCOMES OF GLOFITAMAB AND EPCORITAMAB IN R/R DLBCL ELDERLY PATIENTS: A REAL‐WORLD EVIDENCE STUDY FROM THE CUBIC CONSORTIUMAmrita Chauhan, Liangyi Chen, Sairah Ahmed et al.|Hematological Oncology|2025Cited by 0
Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortiumChijioke Nze, Narendranath Epperla, Allison M. Bock et al.|Blood|2025Cited by 0
Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomasAndrew Jallouk, Sairah Ahmed, Lorenzo Falchi et al.|Blood|2025Cited by 0
Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphomaPierre Stéphan, Jennifer L. Crombie, Karan Chohan et al.|Blood|2025Cited by 0